Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Roberts, L. W. Articles by Lyketsos, C. Search for Related Content PubMed Citation Articles by Roberts, L. W. Articles by Lyketsos, C. Miscellaneous Ethics Schizophrenia Spectrum Disorders Other Research Techniques

Patient and Psychiatrist Ratings of Hypothetical Schizophrenia Research Protocols: Assessment of Harm Potential and Factors Influencing Participation Decisions

OBJECTIVE: A central ethical issue in schizophrenia research is whether participants are able to provide informed consent, particularly for protocols entailing medication washouts or placebo treatments. Few data show how patients with schizophrenia and psychiatrists assess such scientific designs regarding potential harm, willingness to participate, and the relative influence of clinicians, family members, and financial incentives upon participation decisions. METHOD: In this preliminary study, structured interviews were conducted with schizophrenia patients (N=59), and parallel surveys were completed by attending and resident psychiatrists (N=70). Four hypothetical research protocols were rated. Patients were asked about their own views; psychiatrists provided both their personal views and predictions of patient views. RESULTS: Patients and psychiatrists both perceived substantially different levels of harm across the four protocols, identifying significantly greater harm for medication washouts or placebo treatments. Participants were less willing to enroll in protocols perceived as more harmful. Schizophrenia patients found enrollment decisions relatively easy. Patients and psychiatrists indicated that doctor recommendations, monetary incentives, and, to a lesser extent, family preferences had a mild influence on participation decisions. CONCLUSIONS: Given hypothetical protocols with variable design elements, schizophrenia patients and psychiatrists made meaningful and discerning harm assessments and participation decisions. These findings suggest that schizophrenia patients may have strengths in the research consent process that may not be fully recognized. The impact of outside influences upon research enrollment decisions remains uncertain. While psychiatrists were often accurate in predicting patient responses, data suggest the importance of clarifying views of individual patients regarding specific protocols.

This article has been cited by other articles:

				L. B. Dunn, D. S. Kim, I. E. Fellows, and B. W. Palmer Worth the Risk? Relationship of Incentives to Risk and Benefit Perceptions and Willingness to Participate in Schizophrenia Research Schizophr Bull, July 1, 2009; 35(4): 730 - 737. [Abstract] [Full Text] [PDF]

				P. T. Yanos, B. S. Stanley, and C. S. Greene Research Risk for Persons With Psychiatric Disorders: A Decisional Framework to Meet the Ethical Challenge Psychiatr Serv, March 1, 2009; 60(3): 374 - 383. [Abstract] [Full Text] [PDF]

				K K Anderson and S D Mukherjee The need for additional safeguards in the informed consent process in schizophrenia research J. Med. Ethics, November 1, 2007; 33(11): 647 - 650. [Abstract] [Full Text] [PDF]

				L. W. Roberts, T. D. Warner, K. G. Hammond, and L. B. Dunn Assessments by Patients With Schizophrenia and Psychiatrists of Relative Risk of Research Procedures Psychiatr Serv, November 1, 2006; 57(11): 1629 - 1635. [Abstract] [Full Text] [PDF]

				L. W. Roberts, K. G. Hammond, and J. Hoop An Inverse Relationship Between Perceived Harm and Participation Willingness in Schizophrenia Research Protocols Am J Psychiatry, November 1, 2006; 163(11): 2002 - 2004. [Abstract] [Full Text] [PDF]

				C. B. Fisher, C. D. Cea, P. W. Davidson, and A. L. Fried Capacity of Persons With Mental Retardation to Consent to Participate in Randomized Clinical Trials Am J Psychiatry, October 1, 2006; 163(10): 1813 - 1820. [Abstract] [Full Text] [PDF]

				P. F. Schulte Risk of Clozapine-Associated Agranulocytosis and Mandatory White Blood Cell Monitoring Ann. Pharmacother., April 1, 2006; 40(4): 683 - 688. [Abstract] [Full Text] [PDF]

				L. B. Dunn, B. W. Palmer, M. Keehan, D. V. Jeste, and P. S. Appelbaum Assessment of Therapeutic Misconception in Older Schizophrenia Patients With a Brief Instrument Am J Psychiatry, March 1, 2006; 163(3): 500 - 506. [Abstract] [Full Text] [PDF]

				L. B Dunn, P. J Candilis, and L. W. Roberts Emerging Empirical Evidence on the Ethics of Schizophrenia Research Schizophr Bull, January 1, 2006; 32(1): 47 - 68. [Abstract] [Full Text] [PDF]

				L. W. Roberts, L. B Dunn, K. A Green Hammond, and T. D Warner Do Research Procedures Pose Relatively Greater Risk for Healthy Persons Than for Persons With Schizophrenia? Schizophr Bull, January 1, 2006; 32(1): 153 - 158. [Abstract] [Full Text] [PDF]

				L. B Dunn, B. W Palmer, and M. Keehan Understanding of Placebo Controls Among Older People With Schizophrenia Schizophr Bull, January 1, 2006; 32(1): 137 - 146. [Abstract] [Full Text] [PDF]

				P. J Candilis, C. M A Geppert, K. E Fletcher, C. W Lidz, and P. S Appelbaum Willingness of Subjects With Thought Disorder to Participate in Research Schizophr Bull, January 1, 2006; 32(1): 159 - 165. [Abstract] [Full Text] [PDF]

				L. W. Roberts, T. D Warner, K. G. Hammond, and J. G Hoop Views of People With Schizophrenia Regarding Aspects of Research: Study Size and Funding Sources Schizophr Bull, January 1, 2006; 32(1): 107 - 115. [Abstract] [Full Text] [PDF]

				G. Kemmler, M. Hummer, C. Widschwendter, and W. W. Fleischhacker Dropout Rates in Placebo-Controlled and Active-Control Clinical Trials of Antipsychotic Drugs: A Meta-analysis Arch Gen Psychiatry, December 1, 2005; 62(12): 1305 - 1312. [Abstract] [Full Text] [PDF]

				B. E. McDermott, J. B. Gerbasi, C. Quanbeck, and C. L. Scott Capacity of Forensic Patients to Consent to Research: The Use of the MacCAT-CR J Am Acad Psychiatry Law, September 1, 2005; 33(3): 299 - 307. [Abstract] [Full Text] [PDF]

				K. J. Prentice, J. M. Gold, and W. T. Carpenter Jr. Optimistic Bias in the Perception of Personal Risk: Patterns in Schizophrenia Am J Psychiatry, March 1, 2005; 162(3): 507 - 512. [Abstract] [Full Text] [PDF]

				J. A. Kovnick, P. S. Appelbaum, S. K. Hoge, and R. A. Leadbetter Competence to Consent to Research Among Long-Stay Inpatients With Chronic Schizophrenia Psychiatr Serv, September 1, 2003; 54(9): 1247 - 1252. [Abstract] [Full Text] [PDF]

				W. W. Fleischhacker, P. Czobor, M. Hummer, G. Kemmler, R. Kohnen, and J. Volavka Placebo or Active Control Trials of Antipsychotic Drugs? Arch Gen Psychiatry, May 1, 2003; 60(5): 458 - 464. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us